Successful Tender of CureVac Shares
The recent developments surrounding BioNTech's offer for CureVac shares mark a significant milestone in the ongoing exchange process. An impressive total of 184,071,410 shares of CureVac N.V. have been tendered, which corresponds to approximately 81.74% of the company's total issued and outstanding shares. This substantial participation confirms that the minimum condition for the exchange offer has been met, paving the way for the successful execution of the acquisition.
Subsequent Offering Period Announced
Following the initial offering period, BioNTech has launched a subsequent offering phase for CureVac shareholders. This window allows those who have yet to participate the chance to tender their shares. The expiration date for this subsequent offering period is set for 12:01 a.m. Eastern Time. This move aims to ensure that all eligible shareholders have the opportunity to take part in this significant transaction.
Details of the Post-Offer Reorganization
Looking ahead, the post-offer reorganization is projected to commence shortly after the completion of the subsequent offering period. This strategic reorganization is designed to facilitate the transition for those shareholders who chose not to tender their shares. As part of this process, these shareholders will receive BioNTech American Depositary Shares (ADSs), along with a possible cash equivalent for fractional ADSs. It’s important to note that adhering to the reorganization terms will subject non-tendering shareholders to a 15% Dutch dividend withholding tax.
Trading Status of Non-Tendering Shares
After the post-offer reorganization is finalized, shares held by shareholders who did not tender will become non-tradable on any national stock exchanges and may be subject to further transfer restrictions. This underscores the importance for shareholders to carefully consider their options during this crucial transaction period.
About BioNTech and Its Mission
At the forefront of biopharmaceutical innovation, BioNTech SE (NASDAQ: BNTX) is dedicated to developing groundbreaking immunotherapies that target cancer and other serious illnesses. The company’s strong commitment to research and development has led to an expansive portfolio, which includes mRNA cancer treatments, immunomodulators, and targeted therapies like antibody-drug conjugates and chimeric antigen receptor (CAR) T cell therapies. BioNTech’s expertise in mRNA tech and partnerships with renowned pharmaceutical entities enhance its capabilities to create effective solutions for a variety of health challenges.
Contacting BioNTech for More Information
For those seeking additional insight into this exchange offer or any aspects of BioNTech's latest initiatives, reaching out to the Investor Relations department can provide valuable assistance. You can connect via email at Investors@BioNTech.de. The Media Relations team can be contacted at Media@BioNTech.de as well.
Frequently Asked Questions
What is the minimum condition for the CureVac exchange offer?
BioNTech has satisfied the minimum condition by obtaining tenders for 184,071,410 shares, which is approximately 81.74% of CureVac’s outstanding shares.
What happens in the subsequent offering period?
Shareholders who have not yet tendered their shares can do so during the subsequent offering period, which will expire at 12:01 a.m. Eastern Time.
What will happen to non-tendering CureVac shareholders?
Non-tendering shareholders will receive BioNTech ADSs during the post-offer reorganization and will be subject to certain tax implications.
Where can I find more information about BioNTech?
Additional information can be found on BioNTech's official website at www.BioNTech.com.
Who should I contact for investor inquiries?
For investor inquiries, you can contact BioNTech’s Investor Relations department at Investors@BioNTech.de.
